Court invalidates two CINVANTI patents; Heron to appeal to Federal Circuit

HERON THERAPEUTICS, INC. /DE/

U.S. District Court for Delaware ruled claims of Patents 12,115,255 and 12,290,520 invalid on June 1, 2026.
Decision does not affect prior settlements for CINVANTI or APONVIE injectable emulsions.
Heron intends to appeal to the Federal Circuit, a court specializing in patent disputes.
CEO Craig Collard said company will vigorously pursue appeal and all available remedies.
Litigation with Azurity (formerly Slayback) involves a generic version of CINVANTI.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.